PEA

Palmitoylethanolamide (PEA) is a lipid-like substance that the body itself makes in almost all its tissues. It is also present in small amounts in foods such as egg yolk, soy and peanuts.

Quick facts

  • The body produces it naturally in almost all its tissues

PEA was first described in the 1950s while studying egg yolk, and today it is one of the endogenous molecules attracting most research interest.

What is PEA?

Palmitoylethanolamide is a fatty acid amide from the same family as anandamide. The body produces it on demand in cell membranes, and its tissue levels vary according to the needs of each moment.

How does it work?

  • It binds to the PPAR-alpha receptor, which helps regulate genes related to fat metabolism and tissue responses.
  • It modulates the activity of mast cells and glial cells, which are involved in communication between the immune and nervous systems.
  • It interacts with the endocannabinoid system indirectly, without binding to cannabinoid receptors or having psychoactive effects.

What does the science say?

Most clinical trials with PEA have been carried out in medical settings, and a 2017 meta-analysis pooled their results (Artukoglu 2017). These data cannot be applied directly to a food supplement, and PEA has no authorised health claims in the European Union.

Dose and how to take it

  • Studies usually use between 600 and 1,200 mg a day, in one or two doses.
  • Micronised forms have a smaller particle size, intended to make absorption easier.
  • At IVB, ZeroDol provides 500 mg of PEA per capsule.

Safety

  • In published studies it has been well tolerated and no relevant interactions have been described.
  • There is not enough data in pregnancy, breastfeeding or children: talk to your healthcare professional.

Frequently asked questions

What is PEA used for?

It is a molecule the body produces to regulate its tissues' responses. It is researched mainly in clinical settings; as a food supplement it has no authorised health claims in the EU.

Is PEA a cannabinoid?

No. It belongs to the same chemical family as some endocannabinoids, but it does not bind to their receptors, does not come from cannabis and has no psychoactive effects.

How long should PEA be taken?

Most studies last 4 to 12 weeks. Follow the product directions or your healthcare professional's advice.

Which foods contain PEA?

Egg yolk, soy, peanuts and milk, although in very small amounts compared with those used in studies.

References
  1. Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017;20(5):353-362.
  2. Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174(11):1349-1365.
Essential line

ZeroDol

CHF 28.11 CHF 23.90
4.88
(86)
Dietary supplement based on palmitoylethanolamide (PEA)

Clinical Studies

PEA: Natural pain reliever for everyone

A recent meta-analysis of 11 randomized controlled trials on the effectiveness of PEA supplementation in participants suffering from chronic pain due to a variety of conditions including spinal cord injury, endometriosis, irritable bowel syndrome (IBS), carpal tunnel syndrome, temporomandibular joint arthritis (TMJ), vestibulodynia, burning mouth syndrome, diabetic neuropathy, knee osteoarthritis, dysmenorrhea, and regular use of injectable medications for multiple sclerosis showed that PEA may be an effective and well-tolerated treatment for chronic pain.

Read more Read less
Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients. 2023;

The PEA reduces pain intensity

The following study evaluated the effects of PEA on pain modulation in 14 healthy volunteers using a randomized, double-blind, crossover trial. The results showed that PEA reduced induced pain intensity, improved pain tolerance and conditioned pain modulation, with no adverse effects.

Read more Read less
Klivinyi C, Lang-Illievich K, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H. The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers—A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Nutrients. 2022; 4(19):4084.

The PEA in neuropathic pain

This 2022 study evaluated the safety and efficacy of PEA in 70 patients with diabetic neuropathic pain. After 8 weeks of treatment, PEA reduced pain, improved sleep quality, and decreased systemic inflammation without significant adverse effects.

Read more Read less
Pickering, E., Steels, E. L., Steadman, K. J., Rao, A., & Vitetta, L. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology, 2023; 30(6), 2063–2077.